The BENeFiTS Clinical Trial A Phase 1b clinical trial of PB-04 in beta-thalassemia & sickle cell disease has completed enrollment. Click here for more..
5th IND Approved by FDA
Our current lead therapeutic suppresses BCL-11A, a repressor of an endogenous globin gene, which is known to ameliorate certain hemoglobin diseases – providing "gene therapy in a capsule.” Read more here.
Celebrating International Thalassemia Day On May 8 we will be celebrating World Thalassemia Day with patients, families and the Phoenicia BioScience Team! Click here to read more.
We consult on translation of preclinical discoveries into the clinic, early to late development strategy and execution. We can assist with trial design, medical rationale and documents, and medical monitoring.
At Phoenicia, we strive to advance the development of therapeutics for medical conditions with unmet needs, from our own discovery program and from others.
Viracell Inc. has licensed our PKC delta inhibitor technology.
The Viral Activation Program is in development by Viracta Therapeutics.
Phoenicia Founders and Principals have developed therapeutics to modulate innate silenced genes to treat serious genetic blood diseases, sickle cell disease and beta thalassemia, and viral-associated malignancies, such as lymphomas associated with the Epstein Barr Virus.
An early program demonstrated proof-of-principle of fetal hemoglobin induction in sickle cell disease and beta thalassemia.
A next-generation therapeutic which suppresses 3 repressors of the fetal globin gene has been co-developed with the NCATS-TRND Program and approved for a proof-of-concept clinical trial by the US FDA and Health Canada.
A small molecule which augments STAT-5 signaling enhances hematologic recovery following radiation and chemotherapy.
What are β-hemoglobinopathies?
The most common type of genetic diseases world-wide. Disorders of hemoglobin, the protein in red blood cells which delivers oxygen.
Major features:
Hemolytic anemia
Organ damage
Early mortality
What are some of your current translational programs?
Therapeutic activation of developmentally silenced genes to replace the function of mutated hemoglobin genes
Targeting a pathway which allows cancer cells to escape normal cellular death signals
Enhancing proliferation of hematopoietic cells to accelerate recovery from acute radiation sickness, transplantation and chemotherapy, or inherited cytopenia
Refining therapies to heal refractory wounds
How do I contact you?
You can contact us by navigating to the contact page and filling out the contact form.
Do you assist with grants?
Yes. We provide assistance with the strategy, writing, and assembly of SBIR and STTR applications. Please use the contact page to reach out.
